| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 12/30/2009 | CA2728511A1 Sulfonamide compounds or salts thereof |
| 12/30/2009 | CA2728128A1 6-substituted isoquinolines and isoquinolinones |
| 12/29/2009 | US7638556 Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof |
| 12/29/2009 | US7638551 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 12/29/2009 | US7638546 Imidazolyl derivatives |
| 12/29/2009 | US7638540 Benzofuran compound and medicinal composition containing the same |
| 12/29/2009 | US7638538 4-chloro-N-({5-[({2-[(2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide; inhibitor of jun N-terminal kinase 2 and 33 inhibitor; autoimmune disorders |
| 12/29/2009 | US7638536 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally |
| 12/29/2009 | US7638528 Drug delivery agent containing an anticarcinogenic agent such as mitoxanthrone, doxorubicin, methotrexate etc. covalently linked to a compound via an ester, amido or carabamte linkage to the S, O or amino group of the compound |
| 12/29/2009 | US7638520 Pyrimidine compounds |
| 12/29/2009 | US7638511 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS) |
| 12/29/2009 | US7638502 Treatment of EBV and KHSV infection and associated abnormal cellular proliferation |
| 12/29/2009 | US7638480 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 12/29/2009 | US7638149 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |
| 12/29/2009 | US7638141 Generating multipotent cells from sstem cells isolated from residual cord blood; tissue engineering and regenerative medicine |
| 12/29/2009 | US7638129 Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone |
| 12/29/2009 | CA2477851C Small molecule entry inhibitors |
| 12/29/2009 | CA2466490C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 12/29/2009 | CA2465877C Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 12/29/2009 | CA2464768C Method and composition for potentiating an opiate analgesic |
| 12/29/2009 | CA2451932C Pyrrolopyrimidines as protein kinase inhibitors |
| 12/29/2009 | CA2447521C Delivery of antihistamines through an inhalation route |
| 12/29/2009 | CA2429720C Tricyclic compounds useful for the inhibition of farnesyl protein transferase |
| 12/29/2009 | CA2428133C Indolylmaleimide derivatives as protein kinase c inhibitors |
| 12/29/2009 | CA2425215C Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 12/29/2009 | CA2424797C Methods of inducing cancer cell death and tumor regression |
| 12/29/2009 | CA2415683C Indoloquinazolinones |
| 12/29/2009 | CA2410311C Barbituric acid analogs as therapeutic agents |
| 12/29/2009 | CA2384624C Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 12/29/2009 | CA2367507C Angiogenesis using three-dimensional stromal tissue constructs |
| 12/29/2009 | CA2348993C Substituted phenethylsulfones and method of reducing tnf.alpha. levels |
| 12/29/2009 | CA2339054C E-isomeric fullerene derivatives |
| 12/29/2009 | CA2338543C Method of direct identification of compound efficacy at a g protein-coupled orphan receptor |
| 12/29/2009 | CA2287214C Substituted benzopyran derivatives for the treatment of inflammation |
| 12/24/2009 | US20090318565 Novel Compositions for the Enhancement of the Anti-oxidant Potential of Hydrogenated Curcuminoids or Combinations Thereof |
| 12/24/2009 | US20090318556 Biomarkers for detecting radiation exposure: methods and uses thereof |
| 12/24/2009 | US20090318513 Compounds exhibiting thrombopoietin receptor agonism |
| 12/24/2009 | US20090318482 Tablet preparation without causing a tableting trouble |
| 12/24/2009 | US20090318452 INHIBITORS OF p38 |
| 12/24/2009 | US20090318390 Combinations comprising epothilones and pharmaceutical uses thereof |
| 12/24/2009 | US20090318383 Compositions and methods for modulation of vascular structure and/or function |
| 12/24/2009 | US20090318365 Metastin derivatives and use thereof |
| 12/24/2009 | US20090318339 Biodegradable polymers having a pre-determined chirality |
| 12/24/2009 | US20090317471 matrix contains drug (hypotensive agents, antidepressants, anticonvulsants), ionic non-gelling matrix polymer (cellulose acetetate phthalate), and pH modifier; free of gelling or swelling excipient |
| 12/24/2009 | US20090317443 Coated implant |
| 12/24/2009 | US20090317413 Detection of human platelet antigen (hpa) antibodies |
| 12/24/2009 | US20090317398 a labeled polyclonal antibody, monoclonal antibody or antigen-binding fragment which preferentially binds to a polypeptide that chemoattracts peripheral blood monocytes or T-cells; proteins which control development, differentiation, trafficking and physiology of mammalian cells; immunology |
| 12/24/2009 | US20090317389 Fusion molecules and methods for treatment of immune diseases |
| 12/23/2009 | WO2009155611A1 Compositions for the treatment of fibrotic diseases or conditions |
| 12/23/2009 | WO2009154505A1 Membrane stabilising agent |
| 12/23/2009 | WO2009154237A1 Stabilizer for lymph vessel |
| 12/23/2009 | WO2009154230A1 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| 12/23/2009 | WO2009154197A1 Cognitive disorder-ameliorating agent |
| 12/23/2009 | WO2009154190A1 Pyridone compound |
| 12/23/2009 | WO2009154132A1 Spirodiamine-diarylketoxime derivative |
| 12/23/2009 | WO2009154051A1 Immunostimulating agent |
| 12/23/2009 | WO2009153992A1 Cdca1 epitope peptides and vaccines containing the same |
| 12/23/2009 | WO2009153972A1 Agent for prevention of or protection against hypoxic damage comprising mirna as active ingredient |
| 12/23/2009 | WO2009152777A1 A stable and release-controlled rasagiline transdermal patch and method of preparation thereof |
| 12/23/2009 | WO2009152584A1 Synthesis of ageladine a and analogs thereof |
| 12/23/2009 | WO2009133470A3 Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level |
| 12/23/2009 | WO2009133310A3 Combination of dronedarone with at least one diuretic, and therapeutic use thereof |
| 12/23/2009 | WO2009133137A3 Pegylated recombinant human growth hormone compounds |
| 12/23/2009 | EP2135620A1 Ocular hypotensive agent comprising compound capable of inhibiting histone deacetylase as active ingredient |
| 12/23/2009 | EP2135605A2 Therapeutic delivery of carbon monoxide |
| 12/23/2009 | EP2135600A1 Targeting agent for cancer cell or cancer-associated fibroblast |
| 12/23/2009 | EP2134718A2 Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
| 12/23/2009 | EP1549651B1 Pyrimidopyrimidones as kinase inhibitors |
| 12/23/2009 | EP1534390B1 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene hydrazino -2'-hydroxy- 1,1'-biphenyl -3-carboxylic acid bis-(monoethanolamine) |
| 12/23/2009 | EP1483297B1 Antibodies derived from anti ed-b l19 and targeting tumor vasculature |
| 12/23/2009 | EP1450822B1 Polyalkylene oxide conjugates of thiol-containing drugs |
| 12/23/2009 | EP1356816B1 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
| 12/23/2009 | EP1296972B1 Arylmethylamine derivatives for use as tryptase inhibitors |
| 12/23/2009 | EP1274726B1 Therapeutic compounds and methods for modulating v3, a versican isoform |
| 12/23/2009 | EP1259487B1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 12/23/2009 | EP1094837B1 Porcine circovirus and parvovirus vaccine |
| 12/23/2009 | EP0844887B1 Aav transduction of myoblasts |
| 12/23/2009 | CN101611041A Fused heterocyclic compound |
| 12/23/2009 | CN101610779A 5ht4受体拮抗药 5ht4 receptor antagonist |
| 12/23/2009 | CN101610772A Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination |
| 12/23/2009 | CN101610771A Therapeutic agent for liver cancer |
| 12/23/2009 | CN101610767A Combination therapy of substituted oxazolidinones |
| 12/23/2009 | CN101610754A Pharmaceutical composition containing fine particle oil-based suspension |
| 12/23/2009 | CN101607043A Method for treating externally infected wind-cold and vertigo symptoms by soaking feet into Chinese medicament |
| 12/23/2009 | CN101607027A Application of Chinese medicinal composition in preparing medicament for treating chronic fatigue syndrome |
| 12/23/2009 | CN101607016A External medicine for treating swelling from blood stases |
| 12/23/2009 | CN101606932A Application of 17-AAG for preparing eye RPE cell VEGF inhibiting agent |
| 12/23/2009 | CN100572394C Comprehensive extraction process of active components in fresh pilose antler |
| 12/23/2009 | CN100572381C Pyrazolonaphthyridine derivative |
| 12/23/2009 | CN100572372C Salvianolic acid M and rosmarinic acid as aldose reductase inhibitor in sage |
| 12/23/2009 | CN100572363C New imidazole derivative, method for producing the same and use of the same |
| 12/23/2009 | CN100571722C Medicine composition for treating deficiency of the kidney and climacteric syndrome and preparation method thereof |
| 12/23/2009 | CA2728766A1 Compositions for the treatment of fibrotic diseases or conditions |
| 12/23/2009 | CA2728268A1 Cdca1 epitope peptides and vaccines containing the same |
| 12/23/2009 | CA2728156A1 Pyridone compounds |
| 12/23/2009 | CA2727914A1 Spirodiamine-diaryl ketoxime derivative technical field |
| 12/22/2009 | US7635775 Analgesics; central nervous system disorders ; antiarthritic agents; inflammatory bowel disorders; 2-[2-(S or R)-1-(4-chloro-2,5-dimethylbenzenesulfonyl)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]-N-[1-(R)-(pyrrolidin-N-ylcarbonyl-4-guanidino-but-1-yl]acetamide |
| 12/22/2009 | US7635774 Benzimidazole derivatives |
| 12/22/2009 | US7635749 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 12/22/2009 | US7635713 Preterm labor, dysmenorrhea, asthma, hypertension, infertility, sexual disorders, undesired blood clotting, bone disorders, eclampsia, or eosinophil disorder; use in combination with a phosphodiesterase inhibitor; e.g. (5Z)-7-{1-[3-hydroxy-4-(3-methylphenyl)butyl]-3-oxopyrrolidin-2-yl}hept-5-enoic acid |